PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment

Meta-analysis was conducted to systematically assess the effectiveness and safety of programmed cell death protein-1 or ligand-1 (PD-1 or PD-L1) antibodies versus docetaxel alone in advanced non small cell lung cancer (NSCLC). In addition, the prognostic significance of PD-L1 expression in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Qiang, Sun, Zhigang, Zhang, Chenguang, Hou, Yanli, Cao, Bangwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601767/
https://www.ncbi.nlm.nih.gov/pubmed/28938671
http://dx.doi.org/10.18632/oncotarget.19641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601767/
https://www.ncbi.nlm.nih.gov/pubmed/28938671
http://dx.doi.org/10.18632/oncotarget.19641

Ejemplares similares